Huihe Healthcare's K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment
CompanyMedical Device

Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
Company

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth

Genmab's HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
CompanyDeals

Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out

Sichuan Kelun-Biotech's Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC
CompanyDrug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban
Company

Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban

Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
CompanyDrug

Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment

Hansoh Pharmaceutical's Ameile Wins New NMPA Approval for Advanced NSCLC Treatment
CompanyDigital

Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment

IMEIK REGEN Biotech Acquisition Medical Aesthetics Products
CompanyDeals

IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture

Lundbeck's Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy
CompanyDrug

Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy

Shenzhen GeneMind Biosciences Partners with Precisiongenes for Molecular Diagnostic Innovation
CompanyDeals

Shenzhen GeneMind Biosciences Partners with Precisiongenes for Molecular Diagnostic Innovation

Juvensis Therapeutics Heart Gene Therapy Anti-Aging
CompanyDeals

Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke